Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of chronomodulated capecitabine
NL-OMON24089Phase 1Recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Jul 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of capecitabine in cancer, colorectal cancer (CRC), breast cancer and 2 more (2 arms), sponsored by Netherlands Cancer Institute. Primary endpoints: Maximum tolerated dose, Dose-limiting toxicities and 1 more. Started Jul 2014; status: recruiting.
02
Drugs
capecitabine
03
Conditions
cancercolorectal cancer (CRC)breast cancerpancreatic cancer (PC)gastric cancer (GC)
Beyond the preview
Go deeper on NL-OMON24089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON24089.